Respiratory viral infections (RVI) after stem cell transplant (SCT)

Respiratory Viral Infections after Hematopoietic Stem Cell Transplantation in Children

This study was performed to characterize respiratory viral infections in pediatric patients undergoing hematopoietic stem cell transplantation (HSCT). Study samples included 402 respiratory specimens obtained from 358 clinical episodes that occurred in the 116 children of the 175 consecutive HSCT cohort at Seoul National University Children's Hospital, Korea from 2007 to 2010. Multiplex reverse...

Respiratory viral infections in transplant recipients.

A wide range of viruses affect the respiratory tract of transplant recipients, including adenovirus, influenza, human metapneumovirus, parainfluenza virus, respiratory syncytial virus (RSV) and rhinovirus. Prospective studies using contemporary diagnostic techniques have recently improved our understanding of the epidemiology and importance of these respiratory viruses among transplant recipien...

T cells for viral infections after allogeneic hematopoietic stem cell transplant.

Despite recent advances in the field of allogeneic hematopoietic stem cell transplantation (HSCT), viral infections are still a major complication during the period of immune suppression that follows the procedure. Adoptive transfer of donor-derived virus-specific cytotoxic T cells (VSTs) is a strategy to rapidly restore virus-specific immunity to prevent or treat viral diseases after HSCT. Ear...

Antiviral therapies for respiratory viral infections in lung transplant patients.

Because the lung is in constant contact with the environment, infections with respiratory viruses are a common and potentially serious complication of lung transplantation. Infection can cause direct effects, typically manifested as respiratory symptoms and changes in pulmonary function, and indirect effects, such as an enhanced risk of developing chronic allograft rejection. Infections with al...

Clinical and Economic Burden of Respiratory Viral Infections in Hematopoietic Stem Cell Transplant Recipients: The MD Anderson Experience